Related Experiment Videos
Pure red cell aplasia and hepatitis in a child receiving isoniazid therapy
K S Veale1, E S Huff, B K Nelson
1Department of Emergency Medicine, Texas Tech Univesity, El Paso.
The Journal of Pediatrics
|January 1, 1992
Insights
Isoniazid therapy in a child caused pure red cell aplasia, a condition typically seen in adults, and rare hepatitis in a pediatric patient.
Area of Science:
- Pediatric Hematology
- Hepatology
- Pharmacology
Background:
- Isoniazid is a first-line antituberculosis medication.
- Adverse drug reactions to isoniazid are well-documented but vary in presentation.
- Pediatric-specific adverse events require careful monitoring and reporting.
Observation:
- A 7-year-old boy developed severe anemia and liver inflammation while undergoing isoniazid treatment.
- The patient presented with pure red cell aplasia (PRCA), a rare bone marrow disorder.
- Clinically significant hepatitis, uncommon in children, was also observed.
Findings:
- This case highlights the occurrence of PRCA in a pediatric patient receiving isoniazid, a complication previously reported primarily in adults.
- The concurrent development of hepatitis in this child underscores the potential for serious hepatic toxicity from isoniazid in younger populations.
- The combination of PRCA and hepatitis represents a rare and severe adverse drug reaction profile.
Implications:
- This case expands the known spectrum of isoniazid-induced complications in children.
- It emphasizes the need for heightened vigilance and monitoring for both hematologic and hepatic toxicities in pediatric patients treated with isoniazid.
- Further research may be warranted to understand the mechanisms and risk factors for these rare adverse events in children.
Abstract:
A 7-year-old boy had pure red cell aplasia and clinically significant hepatitis during isoniazid therapy. The former complication had been reported only in adults, and the latter is rare in children.